Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute Bioavailability of Selumetinib in Healthy Volunteers
NCT02238782Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selumetinib in neurofibromatosis type 1 (NF1) and solid tumor, sponsored by AstraZeneca. Primary endpoint: Absolute Bioavailability. Started Oct 2014; status: completed.
02
Drugs
selumetinib
03
Conditions
neurofibromatosis type 1 (NF1)solid tumor
Beyond the preview
Go deeper on NCT02238782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02238782.